Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Argenica Therapeutics Ltd ( (AU:AGN) ) just unveiled an update.
Argenica Therapeutics has notified the ASX that director Di Angus ceased to be a director of the company effective 31 December 2025, in line with listing rule disclosure requirements. The filing records that Angus holds 500,000 unlisted options with an exercise price of $0.93 expiring on 31 May 2027, and confirms there are no additional indirect security interests or related contracts disclosed in connection with her departure.
The most recent analyst rating on (AU:AGN) stock is a Hold with a A$0.27 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is an Australian-listed biotechnology company; the release, however, does not provide specific details on its therapeutic focus, products, or target markets.
Average Trading Volume: 210,688
Technical Sentiment Signal: Sell
Current Market Cap: A$37.89M
Learn more about AGN stock on TipRanks’ Stock Analysis page.